A Hawaii Senate committee on Friday approved a bill to set up a state working group to study the therapeutic benefits of psilocybin mushrooms.

There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.

How interested are pharmaceutical companies in psychedelics? While some are hesitant to even discuss where they stand on this restricted class of drugs, a deal inked last month validates the path of at least one company developing next-generation psychedelics.

Cybin announces its Q3 results, supported by a conference call. Cash as of Decemeber 31, 2021 of CAD$63.6 million.

Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.

A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol “PSYK”.

Cheap stocks. Many reasons to invest. We selected five different companies who illustrated these value propositions.

Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.

This morning, Awakn Life Sciences Corp. became the latest psychedelic company to obtain coverage under the H.C. Wainwright umbrella.

Mental health professionals have been exploring psychedelics as a treatment for substance abuse and mental health disorders for decades, and now its status as a legitimate treatment is being recognized in Canada.